Inicio › Linfoma › Misuri › St. Louis
Ensayos clínicos de Linfoma en St. Louis, MO
15 estudios para Linfoma buscan participantes en centros de St. Louis y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
ReclutandoFase 2
- Washington University School of Medicine in St. Louis, St Louis
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ReclutandoFase 1
- Washington University School of Medicine - Oncology Hospital - Public, St Louis
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
ReclutandoFase 1/2
- Washington University School of Medicine in St. Louis, St Louis
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
ReclutandoFase 1
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at West County Hospital, Creve Coeur · A 12 mi de distancia
Collection of Tissue Samples for Cancer Research
ReclutandoEstudio observacional
- Washington University - St. Louis, St Louis
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
ReclutandoFase 1/2
- Washington University School of Medicine, St Louis
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
ReclutandoFase 1
- Washington University School of Medicine, St Louis
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
ReclutandoFase 1
- Washington University School of Medicine/Siteman Cancer Center, St Louis
DALY II USA/ MB-CART2019.1 for DLBCL
ReclutandoFase 2
- Washington University, St. Louis, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Reclutando
- Washington University School of Medicine, St Louis
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ReclutandoEstudio observacional
- Washington University School of Medicine, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
ReclutandoFase 3
- Saint Louis University, St Louis
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
ReclutandoFase 2
- Washington University, St Louis
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
ReclutandoFase 3Se aceptan voluntarios sanos
- OSF Saint Anthony's Health Center, Alton · A 18 mi de distancia
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
ReclutandoFase 1/2
- Washington University, St Louis
Más información sobre Linfoma en MedlinePlus
Ensayos de Linfoma en otras ciudades
- Houston, TX34 estudios
- Boston, MA33 estudios
- New York City, NY33 estudios
- Washington, DC23 estudios
- Baldwin Park, CA21 estudios
- Chicago, IL20 estudios
- Durham, NC17 estudios
- Philadelphia, PA15 estudios
- Cleveland, OH14 estudios
- Edison, NJ12 estudios
- Seattle, WA12 estudios
- Atlanta, GA12 estudios
Otros estudios en St. Louis
- Cáncer de pulmón de células no pequeñas73 estudios
- Cáncer de seno64 estudios
- Cáncer metastásico54 estudios
- Cáncer del colon y del recto50 estudios
- Cáncer (todos los tipos)46 estudios
- Cáncer de próstata46 estudios
- Cáncer de pulmón39 estudios
- Cáncer de ovario38 estudios
- Cáncer de páncreas33 estudios
- Cáncer de endometrio29 estudios
- Carcinoma de células escamosas de cabeza y cuello28 estudios
- Fallo cardíaco26 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.